Document:

Exhibit 4.1

RIGHTS AGREEMENT

 

This Rights Agreement (this “Agreement”)
is made as of October 26, 2021 by and between Deep Medicine Acquisition Corp., a Delaware company with offices at 595 Madison Avenue,
12th Floor, New York, NY 10017 (the “Company”) and American Stock Transfer & Trust Company, LLC, a New York limited liability
trust company, with offices at 6201 15th Avenue, Brooklyn, NY 11219 (“Rights Agent”).

 

WHEREAS, the Company is engaged
in an initial public offering (the “Public Offering”) of units of the Company’s equity securities (the “Public
Units” and, together with the Private Placement Units (as defined below) and the Working Capital Units (as defined below), the “Units”)
to I-Bankers Securities, Inc. (the “Representative”), as representative of the several underwriters (the “Underwriters”),
each such Unit comprised of one share of Class A common stock of the Company, par value $0.0001 per share (“Common Stock”)
and one right to receive one-tenth (1/10) of one share of Common Stock (the “Public Rights” and, together with the Private
Placement Rights (as defined below) and the Working Capital Rights (as defined below), the “Rights”) upon the occurrence of
an Exchange Event (defined below), and in connection therewith, the Company has determined to issue and deliver up to 12,650,000 Public
Rights (including up to 1,650,000 Public Rights subject to the over-allotment option) to public investors in the Public Offering; and

 

WHEREAS, on October 26, 2021,
the Company entered into that certain Unit Subscription Agreements, with Bright Vision Sponsor LLC, a Delaware limited liability company
(“Sponsor”) and the Representative, pursuant to which Sponsor and the Representative will purchase an aggregate of up to 470,000
Units (or up to 519,500 Units if the over-allotment option is exercised) simultaneously with the closing of the Public Offering (and the
closing of the over-allotment option, if applicable), bearing the legend set forth in Exhibit B hereto (“Private Placement
Units”), such Private Placement Units containing 470,000 Rights (or up to 519,500 Rights if the over-allotment option is exercised
in full) (such Rights, collectively, the “Private Placement Rights”);

 

WHEREAS, in order to finance the
Company’s transaction costs in connection with an initial business combination (the “Business Combination”), the Sponsor
or affiliates of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company
funds as the Company may require, of which up to $1,500,000 may be convertible into up to an additional 150,000 Units, bearing the legend
set forth in Exhibit B hereto (“Working Capital Units”), of the post Business Combination entity at a price of $10.00
per Working Capital Unit, and in connection therewith, will issue and deliver up to an aggregate of 150,000 Rights (“Working Capital
Rights”);

 

WHEREAS, the Company has filed
with the Securities and Exchange Commission registration statements on Form S-1, File Nos. 333-259500 and 333-260515 (the “Registration
Statements”), and the prospectus forming a part thereof (collectively, the “Prospectus”), for the registration under
the Securities Act of 1933, as amended, of the Public Units and each of the securities comprising the Public Units, and the shares of
Common Stock underlying the Public Rights; and

 

WHEREAS, the Company desires the
Rights Agent to act on behalf of the Company, and the Rights Agent is willing to so act, in connection with the issuance, registration,
transfer and exchange of the Rights; and

 

WHEREAS, the Company desires to
provide for the form and provisions of the Rights, the terms upon which they shall be issued, and the respective rights, limitation of
rights, and immunities of the Company, the Rights Agent, and the holders of the Rights; and

 

WHEREAS, all acts and things have
been done and performed which are necessary to make the Rights, when executed on behalf of the Company and countersigned by or on behalf
of the Rights Agent, as provided herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery
of this Agreement. 

 

NOW, THEREFORE, in consideration
of the mutual agreements herein contained, the parties hereto agree as follows:

 

    	 	 	 

    	 	 	 

    

1. Appointment of Rights Agent. The Company
hereby appoints the Rights Agent to act as agent for the Company for the Rights, and the Rights Agent hereby accepts such appointment
and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

 

 2. Rights.

 

2.1. Form of Right.
Each Right shall be issued in registered form only, shall be in substantially the form of Exhibit A hereto, the provisions
of which are incorporated herein and shall be signed by, or bear the facsimile signature of, the Chairman of the Board or Chief Executive
Officer and the Secretary of the Company and shall bear a facsimile of the Company’s seal. In the event the person whose facsimile
signature has been placed upon any Right shall have ceased to serve in the capacity in which such person signed the Right before such
Right is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of issuance.

 

2.2. Effect of Countersignature.
Unless and until countersigned by the Rights Agent pursuant to this Agreement, a Right shall be invalid and of no effect and may not be
exchanged for shares of Common Stock.

  

2.3. Registration.

 

2.3.1. Right Register.
The Rights Agent shall maintain books (“Right Register”) for the registration of original issuance and the registration of
transfer of the Rights. Upon the initial issuance of the Rights, the Rights Agent shall issue and register the Rights in the names of
the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Rights Agent by the
Company.

 

2.3.2. Registered Holder.
Prior to due presentment for registration of transfer of any Right, the Company and the Rights Agent may deem and treat the person in
whose name such Right shall be registered upon the Right Register (“registered holder”) as the absolute owner of such Right
and of each Right represented thereby (notwithstanding any notation of ownership or other writing on the Right Certificate made by anyone
other than the Company or the Rights Agent), for the purpose of the exchange thereof, and for all other purposes, and neither the Company
nor the Rights Agent shall be affected by any notice to the contrary.

 

2.4. Detachability of
Rights. The securities comprising the Public Units, including the Public Rights, will begin to trade separately on (i) the 52nd day
after the effectiveness of the Registration Statements, or (ii) such earlier date as the Representative shall determine is acceptable
(the “Detachment Date”). In no event will separate trading of the securities comprising the Public Units commence until the
Company (i) files a Current Report on Form 8-K with the SEC including an audited balance sheet reflecting the Company’s receipt
of the gross proceeds of the Public Offering and (ii) issues a press release announcing when such separate trading will begin.

 

Upon the Detachment Date, the
Public Units will no longer trade, and each holder of Public Units will become, without any action by such holder, the holder of that
number of shares of Common Stock and Public Rights comprising the Public Units held by such holder.

 

2.5. Private Placement Rights
and Working Capital Rights. The Private Placement Rights and Working Capital Rights shall be identical to the Public Rights, except
that so long as they are held by the Sponsor or any of its Permitted Transferees (as defined below) the Private Placement Rights and Working
Capital Rights may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of the Business Combination;
provided, however, that the Private Placement Rights, the Working Capital Rights and any shares of Common Stock held by the Sponsor or
any Permitted Transferees, as applicable, and issued upon conversion of the Private Placement Rights and Working Capital Rights may be
transferred by the holders thereof:

 

(a) to the Company’s officers
or directors, any affiliates or family members of any of the Company’s officers or directors, any members of the Sponsor, or any
of its affiliates;

 

(b) in the case of an individual,
transfers by gift to a member of the individual’s immediate family, to a trust, the beneficiary of which is a member of the individual’s
immediate family or an affiliate of such person, or to a charitable organization;

 

    	 	 	 

    	 	 	 

    

(c) in the case of an individual,
transfers by virtue of laws of descent and distribution upon death of the individual;

 

(d) in the case of an individual,
transfers pursuant to a qualified domestic relations order;

 

(e) transfers by private sales
or transfers made in connection with the consummation of the Business Combination at prices no greater than the price at which the securities
were originally purchased;

 

(f) transfers in the event of
the Company’s liquidation prior to the completion of the Business Combination;

 

(g) transfers by virtue of the
laws of the State of Delaware or the Sponsor’s limited liability company agreement upon dissolution of the Sponsor;

 

(h) in the event of the Company’s
completion of a liquidation, merger, capital stock exchange, reorganization or other similar transaction which results in all of the Company’s
public stockholders having the right to exchange their shares of Common Stock for cash, securities or other property subsequent to the
completion of the Business Combination;

 

provided, however, that in the case
of clauses (a) through (e) or (g) these permitted transferees (the “Permitted Transferees”) must enter into a written agreement(s)
with the Company agreeing to be bound by the transfer and other restrictions in this Agreement and any other agreements between the transferor
and the Company relating to those Private Placement Rights or Working Capital Rights.

 

3. Terms and Exchange of Rights

 

3.1. Rights. Except
in cases where the Company is not the surviving entity after the occurrence of an Exchange Event, each holder of a Right shall automatically
receive one-tenth (1/10) of one share of Common Stock upon the occurrence of an Exchange Event. No additional consideration shall be paid
by a holder of Rights in order to receive his, her or its shares of Common Stock upon an Exchange Event, as the purchase price for such
shares of Common Stock has been included in the purchase price for the Units. In no event will the Company be required to net cash settle
the Rights or issue fractional shares of Common Stock. The provisions of this Section 3.1 may not be modified, amended or deleted without
the prior written consent of the Representative.

 

3.2. Exchange Event.
An “Exchange Event” shall occur upon the Company’s consummation of an initial Business Combination (as defined in the
Company’s Amended and Restated Certificate of Incorporation). 

 

3.3. Exchange of Rights.

 

3.3.1. Issuance of Common
Stock. With respect to the Public Rights, upon the occurrence of an Exchange Event, the Company shall issue to each registered holder
of the Public Rights the number of full shares of Common Stock to which he, she or it is entitled, registered in such name or names as
may be directed by him, her or it and issue to such registered holder(s) a certificate or book-entry position for the such shares. With
respect to the Private Placement Rights or Working Capital Rights, as soon as practicable upon the occurrence of an Exchange Event, the
Company shall direct holders of the Private Placement Rights or Working Capital Rights to return their Rights Certificates to the Rights
Agent. With respect to the Private Placement Rights or Working Capital Rights, upon receipt of a valid Rights Certificate, the Company
shall make (or cause to be made) entries in its Register of Members of the Company and issue to the registered holder of such Private
Placement Rights or Working Capital Rights a certificate or certificates for the number of full shares of Common Stock to which he, she
or it is entitled, registered in such name or names as may be directed by him, her or it. The Company shall not issue fractional shares
upon exchange of Rights. At the time of an Exchange Event, the Company will either instruct the Rights Agent to round down to the nearest
whole share of Common Stock or otherwise inform it how fractional shares will be addressed in accordance with Delaware law.

 

3.3.2. Valid Issuance.
All shares of Common Stock issued upon an Exchange Event in conformity with this Agreement and the Amended and Restated Certificate of
Incorporation of the Company shall be validly issued, fully paid and nonassessable.

    	 	 	 

    	 	 	 

    

  

3.3.3. Date of Issuance.
Each person in whose name any such certificate or book-entry position for Common Stock is issued shall for all purposes be deemed to have
become the holder of record of such shares on the date of the Exchange Event, irrespective of the date of delivery of such certificate
or entry of position.

 

3.3.4 Company Not Surviving
Following Exchange Event. Upon an Exchange Event in which the Company does not continue as the surviving entity, each holder of a
Public Right will automatically receive the one-tenth (1/10) of a share of Common Stock underlying each Right (without paying any additional
consideration) upon the occurrence of an Exchange Event. Each holder of a Private Placement Right or Working Capital Right will be required
to indicate his, her or its election to convert the Private Placement Rights or Working Capital Rights into the underlying shares of Common
Stock as well as to return the original certificates evidencing the Private Placement Rights or Working Capital Rights, if any, to the
Company. 

 

3.5 Duration of Rights.
If an Exchange Event does not occur within the time period set forth in the Company’s Amended and Restated Certificate of Incorporation,
as the same may be amended from time to time, the Rights shall expire and shall be worthless.

    

4. Transfer and Exchange of Rights.

 

4.1. Registration of Transfer.
The Rights Agent shall register the transfer, from time to time, of any outstanding Right upon the Right Register, upon surrender of such
Right for transfer, properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon
any such transfer, a new Right representing an equal aggregate number of Rights shall be issued and the old Right shall be cancelled by
the Rights Agent. The Rights so cancelled shall be delivered by the Rights Agent to the Company from time to time upon request.

 

4.2. Procedure for Surrender
of Rights. Rights may be surrendered to the Rights Agent, together with a written request for exchange or transfer, and thereupon
the Rights Agent shall issue in exchange therefor one or more new Rights as requested by the registered holder of the Rights so surrendered,
representing an equal aggregate number of Rights; provided, however, that in the event that a Right surrendered for transfer bears a restrictive
legend (as in the case of the Private Placement Rights and Working Capital Rights), the Rights Agent shall not cancel such Right and issue
new Rights in exchange therefor until the Rights Agent has received an opinion of counsel for the Company stating that such transfer may
be made and indicating whether the new Rights must also bear a restrictive legend.

 

4.3. Fractional Rights.
The Rights Agent shall not be required to effect any registration of transfer or exchange which will result in the issuance of a Right
Certificate for a fraction of a Right.

 

4.4. Service Charges.
No service charge shall be made for any exchange or registration of transfer of Rights.

 

4.5. Right Execution and
Countersignature. The Rights Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement,
the Rights required to be issued pursuant to the provisions of this Section 4, and the Company, whenever required by the Rights Agent,
will supply the Rights Agent with Rights duly executed on behalf of the Company for such purpose.  

 

5. Other Provisions Relating to Rights of
Holders of Rights.

 

5.1. No Rights as Shareholder.
Until exchange of a Right for Common Stock as provided for herein, a Right does not entitle the registered holder thereof to any of the
rights of a shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise
any preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election
of directors of the Company or any other matter. 

 

5.2. Lost, Stolen, Mutilated,
or Destroyed Rights. If any Right is lost, stolen, mutilated, or destroyed, the Company and the Rights Agent may on such terms as
to indemnity or otherwise as they may in their discretion impose (which shall, in the case of a mutilated Right, include the surrender
thereof), issue a new Right of like denomination, tenor, and date as the Right so lost, stolen, mutilated, or destroyed. Any such new
Right shall constitute a substitute

    	 	 	 

    	 	 	 

    

contractual obligation of the Company, whether or
not the allegedly lost, stolen, mutilated, or destroyed Right shall be at any time enforceable by anyone.

  

5.3. Reservation of Common
Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Common Stock that
will be sufficient to permit the exchange of all outstanding Rights issued pursuant to this Agreement.

 

5.4. Adjustments to Conversion
Ratios. The number of shares of Common Stock that the holders of Rights are entitled to receive as a result of the occurrence of an
Exchange Event shall be equitably adjusted to reflect appropriately the effect of any share split, share dividend, reorganization, recapitalization,
reclassification, combination, exchange of shares or other like change with respect to the shares of Common Stock occurring on or after
the date hereof and prior to the Exchange Event.

 

6. Concerning the Rights Agent and Other Matters.

 

6.1. Payment of Taxes.
The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Rights Agent in respect
of the issuance or delivery of shares of Common Stock upon the exchange of Rights, but the Company shall not be obligated to pay any transfer
taxes in respect of the Rights or such shares.

  

6.2. Resignation, Consolidation,
or Merger of Rights Agent.

 

6.2.1. Appointment of Successor
Rights Agent. The Rights Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further
duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company. If the office of the Rights Agent
becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Rights Agent in place
of the Rights Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after it has been notified
in writing of such resignation or incapacity by the Rights Agent or by the holder of the Right (who shall, with such notice, submit his,
her or its Right for inspection by the Company), then the holder of any Right may apply to the Supreme Court of the State of New York
for the County of New York for the appointment of a successor Rights Agent at the Company’s cost. Any successor Rights Agent, whether
appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good
standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise
corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Rights
Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Rights Agent with
like effect as if originally named as Rights Agent hereunder, without any further act or deed; but if for any reason it becomes necessary
or appropriate, the predecessor Rights Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such
successor Rights Agent all the authority, powers, and rights of such predecessor Rights Agent hereunder; and upon request of any successor
Rights Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually
vesting in and confirming to such successor Rights Agent all such authority, powers, rights, immunities, duties, and obligations.

 

6.2.2. Notice of Successor
Rights Agent. In the event a successor Rights Agent shall be appointed, the Company shall give notice thereof to the predecessor Rights
Agent and the transfer agent for the Common Stock not later than the effective date of any such appointment.

 

6.2.3. Merger or Consolidation
of Rights Agent. Any corporation into which the Rights Agent may be merged or with which it may be consolidated or any corporation
resulting from any merger or consolidation to which the Rights Agent shall be a party shall be the successor Rights Agent under this Agreement
without any further act.   

 

    	 	 	 

    	 	 	 

    

 

6.3. Fees and Expenses
of Rights Agent.

 

6.3.1. Remuneration.
The Company agrees to pay the Rights Agent reasonable remuneration for its services as such Rights Agent hereunder and will reimburse
the Rights Agent upon demand for all expenditures that the Rights Agent may reasonably incur in the execution of its duties hereunder.

 

6.3.2. Further Assurances.
The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such
further and other acts, instruments, and assurances as may reasonably be required by the Rights Agent for the carrying out or performing
of the provisions of this Agreement.

 

6.4. Liability of Rights
Agent.

 

6.4.1. Reliance on Company
Statement. Whenever in the performance of its duties under this Agreement, the Rights Agent shall deem it necessary or desirable that
any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless
other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement
signed by the Chief Executive Officer or Chief Financial Officer and delivered to the Rights Agent. The Rights Agent may rely upon such
statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

6.4.2. Indemnity. The
Rights Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. Subject to Section 6.6 below,
the Company agrees to indemnify the Rights Agent and save it harmless against any and all liabilities, including judgments, costs and
reasonable counsel fees, for anything done or omitted by the Rights Agent in the execution of this Agreement except as a result of the
Rights Agent’s gross negligence, willful misconduct, or bad faith.

 

6.4.3. Exclusions. The
Rights Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution
of any Right (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition
contained in this Agreement or in any Right; nor shall it by any act hereunder be deemed to make any representation or warranty as to
the authorization or reservation of any shares of Common Stock to be issued pursuant to this Agreement or any Right or as to whether any
shares of Common Stock will when issued be valid and fully paid and nonassessable.

 

6.5. Acceptance of Agency.
The Rights Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions
herein set forth.

 

6.6 Waiver. The Rights
Agent hereby waives any right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any
distribution of, the Trust Account (as defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by
and between the Company and the Rights Agent as trustee thereunder) and hereby agrees not to seek recourse, reimbursement, payment or
satisfaction for any Claim against the Trust Account for any reason whatsoever.

  

7. Miscellaneous Provisions.

 

7.1. Successors. All
the covenants and provisions of this Agreement by or for the benefit of the Company or the Rights Agent shall bind and inure to the benefit
of their respective successors and assigns. 

 

7.2. Notices. Any
notice, statement or demand authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Right to or on
the Company shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by certified mail or private courier
service within five days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company
with the Rights Agent), as follows:

 

    	 	 	 

    	 	 	 

    

 

Deep Medicine Acquisition Corp.

595 Madison Avenue, 12th Floor

New York, NY 10017

Attention: Humphrey P. Polanen, Chief Executive
Officer

   

Any notice, statement or demand authorized by this
Agreement to be given or made by the holder of any Right or by the Company to or on the Rights Agent shall be sufficiently given when
so delivered if by hand or overnight delivery or if sent by certified mail or private courier service within five days after deposit of
such notice, postage prepaid, addressed (until another address is filed in writing by the Rights Agent with the Company), as follows:

 

American Stock Transfer & Trust Company,
LLC

6201 15th Avenue

Brooklyn, NY 11219

Attention: Relationship Management

 

7.3. Applicable Law and
Exclusive Forum. The validity, interpretation, and performance of this Agreement and of the Rights shall be governed in all respects
by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the
substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or
relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District
Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be the exclusive forum
for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that such courts
represent an inconvenient forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce
any liability or duty created by the Exchange Act of 1934, as amended, or any other claim for which the federal district courts of the
United States of America are the sole and exclusive forum. Any such process or summons to be served upon the Company may be served by
transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address
set forth in Section 7.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any
action, proceeding or claim.

 

Any person or entity purchasing
or otherwise acquiring any interest in the Rights shall be deemed to have notice of and to have consented to the forum provisions in this
Section 7.3. If any action, the subject matter of which is within the scope the forum provisions above, is filed in a court other than
a court located within the State of New York or the United States District Court for the Southern District of New York (a “Foreign
Action”) in the name of any Right holder, such Right holder shall be deemed to have consented to: (x) the personal jurisdiction
of the state and federal courts located within the State of New York or the United States District Court for the Southern District of
New York in connection with any action brought in any such court to enforce the forum provisions (an “Enforcement Action”),
and (y) having service of process made upon such Right holder in any Enforcement Action by service upon such Right holder’s counsel
in the Foreign Action as agent for such Right holder.

 

7.4. Persons Having Rights
under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended,
or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders
of the Rights and, for the purposes of Sections 3.1, 7.4 and 7.8 hereof, the Representative, any right, remedy, or claim under or by reason
of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. The Representative shall be deemed to be a
third-party beneficiary of this Agreement with respect to Sections 3.1, 7.4 and 7.8 hereof. All covenants, conditions, stipulations, promises,
and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto (and the Representative with
respect to the Sections 3.1, 7.4 and 7.8 hereof) and their successors and assigns and of the registered holders of the Rights. The provisions
of this Section 7.4 may not be modified, amended or deleted without the prior written consent of the Representative.

 

7.5. Examination of the
Right Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Rights Agent in the Borough
of Manhattan, City and State of New York, for inspection by the registered holder of any Right. The Rights Agent may require any such
holder to submit his, her or its Right for inspection by it.

 

    	 	 	 

    	 	 	 

    

7.6. Counterparts.
This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

 

7.7. Effect of Headings.
The Section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

 

7.8 Amendments. This
Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any ambiguity, or
of curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect
to matters or questions arising under this Agreement as the parties may deem necessary or desirable. All other modifications or amendments
shall require the written consent or vote of the registered holders of a majority of the then outstanding Public Rights or the Working
Capital Rights and, with respect to any amendment that solely affects the terms of the Private Placement Rights, the Working Capital Rights
or any provision of this Agreement solely with respect to the Private Placement Rights or the Working Capital Rights, at least a majority
of the number of then-outstanding Private Placement Rights or the Working Capital Rights. The provisions of this Section 7.8 may not be
modified, amended or deleted without the prior written consent of the Representative.

  

7.9 Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the
validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable
term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to
such invalid or unenforceable provision as may be possible and be valid and enforceable.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

    	 	 	 

    	 	 	 

    

IN WITNESS WHEREOF, this Agreement has been duly executed
by the parties hereto as of the day and year first above written.

 

 

	 	DEEP MEDICINE ACQUISITION CORP.
	 	 	 
	 	By:	/s/ Humphrey P. Polanen
	 	 	Name: Humphrey P. Polanen
	 	 	Title: Chief Executive Officer
	 	 	 
	 	AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC
	 	 	 
	 	By:	/s/ Michael A. Nespoli
	 	 	Name: Michael A. Nespoli
	 	 	Title: Executive Director, Relationship Management

  

[Signature Page to Rights Agreement]

 

  

 

  

 

    	 	 	 

    	 	 	 

    

 

EXHIBIT A

 

Form of Right

 

 

A-1

 

 

	NUMBER	RIGHTS

 

R ______

 

DEEP MEDICINE ACQUISITION CORP.

INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE

RIGHT

 

SEE REVERSE FOR

CERTAIN DEFINITIONS

CUSIP 243733 110

 

This Certifies that                                                                                                           is
the registered holder of a right or rights (the “Right”) to automatically receive one-tenth of an common stock, par value
US$0.0001 per share, of Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”) for each Right evidenced by
this Right Certificate on the Company's completion of an initial business combination (as defined in the prospectus relating to the Company's
initial public offering (“Prospectus”)) upon surrender of this Right Certificate pursuant to the Rights Agreement between
the Company and American Stock Transfer & Trust Company, LLC. In no event will the Company be required to net cash settle any Right.

 

Upon liquidation of the Company
in the event an initial business combination is not consummated during the required period as identified in the Company’s Amended
and Restated Certificate of Incorporation, the Right(s) shall expire and be worthless. The holder of a Right shall have no right or interest
of any kind in the Company's trust account (as defined in the Prospectus).

 

Upon due presentment for registration
of transfer of the Right Certificate at the office or agency of American Stock Transfer & Trust Company, LLC, the Rights Agent, a
new Right Certificate or Right Certificates of like tenor and evidencing in the aggregate a like number of Rights shall be issued to the
transferee in exchange for this Right Certificate, without charge except for any applicable tax or other governmental charge.

 

The Company and the Rights Agent
may deem and treat the registered holder as the absolute owner of this Right Certificate (notwithstanding any notation of ownership or
other writing hereon made by anyone), for the purpose of any conversion hereof, of any distribution to the registered holder, and for
all other purposes, and neither the Company nor the Rights Agent shall be affected by any notice to the contrary.

 

Holders of Rights are not entitled
to any of the rights of a shareholder of the Company.

 

This Right shall be governed and
construed in accordance with the internal laws of the State of New York, without regard to conflicts of laws principles thereof.

 

	Dated:	 	 
	 	 	 
	 	 	 
	CHIEF EXECUTIVE OFFICER	 	SECRETARY

 

    	 	 	 

    	 	 	 

    

The following abbreviations, when
used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable
laws or regulations:

 

	TEN COM -	as tenants in common	UNIF GIFT MIN ACT -	_____ Custodian ______
	TEN ENT -	as tenants by the entireties	 	(Cust) (Minor)
	JT TEN -	as joint tenants with right of survivorship and not as tenants in common	 	under U.S. Uniform Gifts to Minors
	 	 	 	Act ______________
	 	 	 	               (State)

 

Additional Abbreviations may also be used though not
in the above list.

 

DEEP MEDICINE ACQUISITION CORP.

 

The Company will furnish without
charge to each security holder who so requests the powers, designations, preferences and relative, participating, optional or other special
rights of each class of equity securities or series thereof of the Company and the qualifications, limitations, or restrictions of such
preferences and/or rights. This certificate and the rights represented thereby are issued and shall be held subject to all the provisions
of the Rights Agreement, and all amendments thereto, to all of which the holder of this certificate by acceptance hereof assents.

 

For value received, ___________________________
hereby sell(s), assign(s) and transfer(s) unto

  

PLEASE INSERT SOCIAL SECURITY OR OTHER

 

IDENTIFYING NUMBER OF ASSIGNEE(S)

 

	 
	 

 

	 
	(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE(S))
	 
	 
	 
	 

____________________________________________________________________________________ Rights
represented by the within Certificate, and do hereby irrevocably constitute and appoint

____________________________________________________________________________________Attorney
to transfer the said rights on the books of the within named Company will full power of substitution in the premises.

 

	Dated	 	 	 	 
	 	 	 	Notice:	The signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change whatever.

 

	Signature(s) Guaranteed:	 
	 	 
	 	 

    	 	 	 

    	 	 	 

    

 

	 	 
	THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15).

  

 

 

The holder of this certificate shall have no right or interest of any kind
in or to the funds held in the Company’s trust fund (as defined in the Prospectus).

  

    	 	 	 

    	 	 	 

    

EXHIBIT B

 

Legend

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED
OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN
EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT
BY AND AMONG DEEP MEDICINE ACQUISITION CORP. (THE “COMPANY”), BRIGHT VISION SPONSOR LLC AND THE OTHER PARTIES THERETO,
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE DATE THAT IS THIRTY (30) DAYS AFTER THE DATE
UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN THE RIGHTS AGREEMENT REFERRED TO HEREIN) EXCEPT TO A
PERMITTED TRANSFEREE (AS DEFINED IN THE RIGHTS AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

 

SECURITIES EVIDENCED BY THIS CERTIFICATE AND SHARES
OF COMMON STOCK OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION
RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.Exhibit 10.1

October 26, 2021

 

Deep Medicine Acquisition Corp.

595 Madison Avenue, 12th Floor

New York, NY 10017

 

	Re:	Initial Public Offering

 

Ladies and Gentlemen:

 

This letter (this “Letter Agreement”)
is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”)
entered into by and among Deep Medicine Acquisition Corp., a Delaware corporation (the “Company”), and I-Bankers
Securities, Inc., as representative (the “Representative”) of the several underwriters (each, an “Underwriter”
and collectively, the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”),
of 12,650,000 of the Company’s units (including up to 1,650,000 units that may be purchased to cover over-allotments, if any) (the
“Units”), each comprised of one share of the Company’s Class A common stock, par value $0.0001 per share
(the “Common Stock”), and one right. Each right (a “Right”) entitles
the holder thereof to receive one-tenth (1/10) of one share of Common Stock. The Units will be sold in the Public Offering pursuant to
a registration statements on Form S-1 (File Nos. 333-259500 and 333-260515) and prospectus (the “Prospectus”)
filed by the Company with the U.S. Securities and Exchange Commission (the “Commission”) and the Company has
applied to have the Units listed on The Nasdaq Global Market. Certain capitalized terms used herein are defined in paragraph 11 hereof.

 

In order to induce the Company and the Underwriters to enter into the Underwriting
Agreement and to proceed with the Public Offering and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, each of Bright Vision Sponsor LLC (the “Sponsor”), and the undersigned individuals,
each of whom is a member of the Company’s board of directors and/or management team or an advisor of the Company (each, an “Insider”
and collectively, the “Insiders”) and Representative, hereby agrees with the Company as follows:

 

1. The Sponsor, Representative and each Insider agrees
that if the Company seeks stockholder approval of a proposed Business Combination, then in connection with such proposed Business Combination,
it, he or she shall (i) vote any shares of Capital Stock owned by it, him or her in favor of any proposed Business Combination and (ii)
not redeem any shares of Common Stock owned by it, him or her in connection with such stockholder approval. If the Company engages in
a tender offer in connection with any proposed Business Combination, the Sponsor, Representative and each Insider agrees that it, he or
she will not seek to sell its, his or her shares of Capital Stock to the Company in connection with such tender offer.

 

2. (a) The Sponsor, and each Insider hereby agrees
that in the event that the Company fails to consummate a Business Combination within the timeframe set forth in the Company’s second
amended and restated certificate of incorporation, as it may be amended from time to time (the “Charter”) and
Section 2(a) herein, the Sponsor, and each Insider shall take all reasonable steps to cause the Company to (i) cease all operations except
for the purpose of winding up, (ii) as promptly as reasonably possible but not more than 10 business days thereafter, subject to lawfully
available funds therefor, redeem 100% of the Common Stock sold as part of the Units in the Public Offering (the “Offering Shares”),
at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account (as defined below), including
interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $50,000
of interest to pay dissolution expenses), divided by the number of then outstanding Offering Shares, which redemption will completely
extinguish all Public Stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if
any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the
Company’s remaining stockholders and the Company’s board of directors, dissolve and liquidate, subject in the case of clauses
(ii) and (iii) to the Company’s obligations under Delaware law to provide for claims of creditors and other requirements of applicable
law. The Sponsor, Representative and each Insider agrees not to propose any amendment to the Charter to modify (i) the substance or timing
of the ability of holders of Offering Shares to seek redemption in connection with a Business Combination or amendments to the Charter
prior thereto or (ii) (A) the Company’s

    	 	 	 

    	 	 	 

    

obligation to redeem 100% of the Offering Shares if the Company does not
complete a Business Combination within such time set forth in the Charter or (B) any other provisions relating to stockholders' rights
or pre-initial Business Combination activity, unless the Company provides its public stockholders with the opportunity to redeem their
shares of Common Stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on
deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company
to pay its taxes, divided by the number of then outstanding Offering Shares.

 

(b) The Sponsor, Representative and each Insider acknowledges
that it, he or she has no right, title, interest or claim of any kind in or to any monies held in the Trust Account or any other asset
of the Company as a result of any liquidation of the Company with respect to the Founder Shares or Common Stock underlying the Private
Placement Units held by it, him or her. The Sponsor, Representative and each Insider hereby further waives, with respect to any shares
of Common Stock held by it, him or her, if any, whether acquired now or hereafter, any redemption rights it, he or she may have in connection
with the consummation of a Business Combination or amendments to the Charter prior thereto, including, without limitation, any such rights
available in the context of a stockholder vote to approve such Business Combination or a stockholder vote to approve an amendment to the
Charter to modify (i) (A) the substance or timing of the Company’s obligation to redeem 100% of the Offering Shares if the Company
has not consummated a Business Combination within the time period set forth in the Charter or (B) any other provisions relating to stockholders'
rights or pre-initial Business Combination activity or (ii) in the context of a tender offer made by the Company to purchase shares of
Common Stock (although the Sponsor, the Insiders and their respective affiliates shall be entitled to redemption and liquidation rights
with respect to any Offering Shares it or they hold if the Company fails to consummate a Business Combination within the time period set
forth in the Charter).

 

3. During the period commencing on the date of the
Underwriting Agreement and ending 180 days after such date, the Sponsor, Representative and each Insider shall not, without the prior
written consent of the Representative, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase
or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and the rules and regulations of the Commission promulgated thereunder, with respect to any Units, shares of Capital
Stock, Rights or any securities convertible into, or exercisable, or exchangeable for, shares of Capital Stock owned by it, him or her,
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of any Units, shares of Capital Stock, Rights or any securities convertible into, or exercisable, or exchangeable for, shares of Capital
Stock owned by it, him or her, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or
(iii) publicly announce any intention to effect any transaction specified in clause (i) or (ii). Each of the Insiders, the Sponsor and
Representative acknowledges and agrees that, prior to the effective date of any release or waiver, of the restrictions set forth in this
paragraph 3 or paragraph 7 below, the Company shall announce the impending release or waiver by press release through a major news service
at least two business days before the effective date of the release or waiver. Any release or waiver granted shall only be effective two
business days after the publication date of such press release. The provisions of this paragraph will not apply if the release or waiver
is effected solely to permit a transfer not for consideration and the transferee has agreed in writing to be bound by the same terms described
in this Letter Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

 

4. In the event of the liquidation of the Trust Account
upon the failure of the Company to consummate its initial Business Combination within the time period set forth in the Charter, the Sponsor
(the “Indemnitor”) agrees to indemnify and hold harmless the Company against any and all loss, liability, claim,
damage and expense whatsoever (including, but not limited to, any and all legal or other expenses reasonably incurred in investigating,
preparing or defending against any litigation, whether pending or threatened) to which the Company may become subject as a result of any
claim by (i) any third party for services rendered or products sold to the Company or (ii) any prospective target business with which
the Company has entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement
(a “Target”); provided, however, that such indemnification of the Company by the Indemnitor shall
(x) apply only to the extent necessary to ensure that such claims by a third party or a Target do not reduce the amount of funds in the
Trust Account to below the lesser of (i) $10.10 per Offering Share and (ii) the actual amount per Offering Share held in the Trust Account
as of the date of

    	 	 	 

    	 	 	 

    

the liquidation of the Trust Account, if less than $10.10 per Offering
Share is then held in the Trust Account due to reductions in the value of the trust assets, less interest earned on the Trust Account
which may be withdrawn to pay taxes, (y) not apply to any claims by a third party or a Target which executed a waiver of any and all rights
to the monies held in the Trust Account (whether or not such waiver is enforceable) and (z) not apply to any claims under the Company’s
indemnity of the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended. The Indemnitor
shall have the right to defend against any such claim with counsel of its choice reasonably satisfactory to the Company if, within 15
days following written receipt of notice of the claim to the Indemnitor, the Indemnitor notifies the Company in writing that it shall
undertake such defense.

    

5. To the extent that the Underwriters do not exercise
their over-allotment option to purchase up to an additional 1,650,000 Units in full within 30 days from the date of the Prospectus (and
as further described in the Prospectus), the Sponsor agrees to forfeit, at no cost, a number of Founder Shares in the aggregate equal
to 412,500 multiplied by a fraction, (i) the numerator of which is 1,650,000 minus the number of Units purchased by the Underwriters upon
the exercise of their over-allotment option, and (ii) the denominator of which is 1,650,000. The Sponsor will be required to forfeit only
that number of Founder Shares as is necessary so that the Initial Stockholders will own an aggregate of 20.0% of the Company’s issued
and outstanding shares of Capital Stock after the Public Offering (excluding the shares of Common Stock underlying the Private Placement
Units and the shares of Common Stock issuable to the Representative).

 

6. The Sponsor, Representative and each Insider hereby
agrees and acknowledges that: (i) the Underwriters and the Company would be irreparably injured in the event of a breach by such Sponsor,
Representative or an Insider of its, his or her obligations under paragraphs 1, 2(a), 2(b), 3, 4, 5, 7(a), 7(b), and 9, as applicable,
of this Letter Agreement (ii) monetary damages may not be an adequate remedy for such breach and (iii) the non-breaching party shall be
entitled to injunctive relief, in addition to any other remedy that such party may have in law or in equity, in the event of such breach.

 

7. (a) The Sponsor and each Insider agrees that it,
he or she shall not Transfer (i) 50% of Founder Shares (or shares of Common Stock issuable upon conversion thereof) and any post-Business
Combination shares until the earlier of (A) six months after the completion of the Company’s initial Business Combination or (B)
subsequent to the Business Combination, (x) if the closing price of the Common Stock equals or exceeds $12.50 per share (as adjusted for
stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period
commencing after the Company’s initial Business Combination or (y) the date on which the Company completes a liquidation, merger,
capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the
right to exchange their shares of Common Stock for cash, securities or other property and (ii) the remaining 50% of Founder Shares (or
shares of Common Stock issuable upon conversion thereof) and any post-Business Combination shares until the earlier of (A) six months
after the completion of the Company’s initial Business Combination or (B) subsequent to the Business Combination, the date on which
the Company completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of
the Company’s stockholders having the right to exchange their shares of Common Stock for cash, securities or other property (the
“Founder Shares Lock-up Period”).

 

(b) The Sponsor, Representative and each Insider agrees
that it, he or she shall not Transfer any Private Placement Units, Private Placement Rights, Private Placement Shares or shares of Common
Stock issued or issuable upon the conversion of the Private Placement Rights until 30 days after the completion of a Business Combination
(the “Private Placement Lock-up Period”, together with
the Founder Shares Lock-up Period, the “Lock-up Periods”).

 

(c) Notwithstanding the provisions set forth in paragraphs
7(a) and (b), Transfers of the Founder Shares, Private Placement Units, Private Placement Rights, Private Placement Shares and shares
of Common Stock issued or issuable upon the conversion of the Private Placement Rights or the Founder Shares that are held by the Sponsor,
Representative, any Insider or any of their permitted transferees (that have complied with this paragraph 7(c)), are permitted (a) to
the Company’s officers or directors, any affiliate or family member of any of the Company’s officers or directors or any affiliate
of the Sponsor or to any member(s) of the Sponsor; (b) in the case of an individual, by gift to a member of such individual’s immediate
family or to a trust, the beneficiary of which is a member of such individual’s immediate family, an affiliate of such individual
or to a charitable organization; (c) in

    	 	 	 

    	 	 	 

    

the case of an individual, by virtue of laws of descent and distribution
upon death of such individual; (d) in the case of an individual, pursuant to a qualified domestic relations order; (e) by private sales
or transfers made in connection with the consummation of an initial Business Combination at prices no greater than the price at which
the securities were originally purchased; (f) in the event of the Company’s liquidation prior to the completion of an initial Business
Combination; or (g) by virtue of the laws of the State of Delaware or the Sponsor’s limited liability company agreement upon dissolution
of the Sponsor; provided, however, that in the case of clauses (a) through (e) or (g), these permitted transferees
must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions herein.

 

8. The Sponsor, Representative and each Insider represents
and warrants that it, he or she has never been suspended or expelled from membership in any securities or commodities exchange or association
or had a securities or commodities license or registration denied, suspended or revoked. Each Insider’s biographical information
furnished to the Company (including any such information included in the Prospectus) is true and accurate in all respects and does not
omit any material information with respect to the Insider’s background. Each Insider’s questionnaire furnished to the Company
is true and accurate in all respects. Each Insider represents and warrants that: it, he or she is not subject to or a respondent in any
legal action for, any injunction, cease-and-desist order or order or stipulation to desist or refrain from any act or practice relating
to the offering of securities in any jurisdiction; it, he or she has never been convicted of, or pleaded guilty to, any crime (i) involving
fraud, (ii) relating to any financial transaction or handling of funds of another person, or (iii) pertaining to any dealings in any securities
and it, he or she is not currently a defendant in any such criminal proceeding.

 

9. Except as disclosed in the Prospectus, neither the
Sponsor nor any officer, director, advisor or any affiliate of the Sponsor, officer, director or advisor of the Company, shall receive
any finder’s fee, reimbursement, consulting fee, monies in respect of any repayment of a loan or other compensation prior to, or
in connection with any services rendered in order to effectuate, the consummation of the Company’s initial Business Combination
(regardless of the type of transaction that it is).

 

10. The Sponsor, Representative and each Insider has
full right and power, without violating any agreement to which it is bound (including, without limitation, any non-competition or non-solicitation
agreement with any employer or former employer), to enter into this Letter Agreement and, as applicable, to serve as an officer and/or
director on the board of directors or an advisor of the Company and hereby consents to being named in the Prospectus as an officer and/or
director of the Company or an advisor of the Company.

 

11. As used herein, (i) “Business Combination”
shall mean a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, involving
the Company and one or more businesses; (ii) “Capital Stock” shall mean, collectively, the
Common Stock and the Founder Shares; (iii) “Founder Shares” shall mean the 3,162,500 shares
of the Company’s Class B common stock, par value $0.0001 per share, initially issued to the Sponsor (up to 412,500 Shares of which
are subject to complete or partial forfeiture by the Sponsor if the over-allotment option is not exercised by the Underwriters) for an
aggregate purchase price of $50,000, or $0.016 per share, prior to the consummation of the Public Offering; (iv) “Initial Stockholders”
shall mean the Sponsor and any Insider that holds Founder Shares; (v) “Private Placement Rights” shall mean
the rights underlying the Private Placement Units; (vi) “Private Placement Shares” shall mean the Common Stock
underlying the Private Placement Units; (vii) “Private Placement Units”
shall mean (a) 380,000 Units (or 406,500 Units if the over-allotment option is exercised in full) that the Sponsor has agreed to purchase
for an aggregate purchase price of $3,800,000 (or $4,065,000 if the over-allotment option is exercised in full), or $10.00 per Unit, and
(b) 90,000 Units (or 113,000 Units if the over-allotment option is exercised in full) that Representative has agreed to purchase for an
aggregate purchase price of $900,000 (or $1,130,000 if the over-allotment option is exercised in full), or $10,00 per Unit, in a private
placement that shall occur simultaneously with the consummation of the Public Offering; (viii) “Public Stockholders”
shall mean the holders of securities issued in the Public Offering; (ix) “Trust Account”
shall mean the trust fund into which a portion of the net proceeds of the Public Offering shall be deposited; and (x) “Transfer”
shall mean the (a) sale of, offer to sell, contract or agreement to sell, hypothecate, pledge, grant of any option to purchase or otherwise
dispose of or agreement to dispose of, directly or indirectly, or establishment or increase of a put equivalent position or liquidation
with respect to or decrease of a call equivalent position within the meaning of Section 16 of the Exchange Act, and the rules and regulations
of the Commission promulgated thereunder with respect to, any security, (b) entry into any swap or other arrangement that transfers to
another, in whole or in part, any of the economic consequences of ownership of any security, whether any such transaction is to

    	 	 	 

    	 	 	 

    

be settled by delivery of such securities, in cash or otherwise, or (c)
public announcement of any intention to effect any transaction specified in clause (a) or (b).

  

12. The Company will
maintain an insurance policy or policies providing directors’ and officers’ liability insurance, and each Director shall be
covered by such policy or policies, in accordance with its or their terms, to the maximum extent of the coverage available for any of
the Company’s directors or officers. 

 

13. This Letter Agreement constitutes the entire agreement
and understanding of the parties hereto in respect of the subject matter hereof and supersedes all prior understandings, agreements, or
representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or
the transactions contemplated hereby. This Letter Agreement may not be changed, amended, modified or waived (other than to correct a typographical
error) as to any particular provision, except by a written instrument executed by all parties hereto.

 

14. No party hereto may assign either this Letter Agreement
or any of its rights, interests, or obligations hereunder without the prior written consent of the other parties. Any purported assignment
in violation of this paragraph shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the
purported assignee. This Letter Agreement shall be binding on the Sponsor, Representative and each Insider and their respective successors,
heirs and assigns and permitted transferees.

 

15. Nothing in this Letter Agreement shall be construed
to confer upon, or give to, any person or corporation other than the parties hereto any right, remedy or claim under or by reason of this
Letter Agreement or of any covenant, condition, stipulation, promise or agreement hereof. All covenants, conditions, stipulations, promises
and agreements contained in this Letter Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors,
heirs, personal representatives and assigns and permitted transferees.

 

16. This Letter Agreement may be executed in any number
of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts
shall together constitute but one and the same instrument.

 

17. This Letter Agreement shall be deemed severable,
and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Letter
Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties
hereto intend that there shall be added as a part of this Letter Agreement a provision as similar in terms to such invalid or unenforceable
provision as may be possible and be valid and enforceable.

 

18. This Letter Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that
would result in the application of the substantive laws of another jurisdiction. The parties hereto (i) all agree that any action, proceeding,
claim or dispute arising out of, or relating in any way to, this Letter Agreement shall be brought and enforced in the courts of New York
City, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive
and (ii) waive any objection to such exclusive jurisdiction and venue or that such courts represent an inconvenient forum.

 

19. Any notice, consent or request to be given in connection
with any of the terms or provisions of this Letter Agreement shall be in writing and shall be sent by express mail or similar private
courier service, by certified mail (return receipt requested), by hand delivery or facsimile transmission.

  

20. This Letter Agreement shall terminate on the earlier
of (i) the expiration of the Lock-up Periods or (ii) the liquidation of the Company; provided, however, that this Letter Agreement shall
earlier terminate in the event that the Public Offering is not consummated and closed by December 31, 2021; provided further that paragraph
4 of this Letter Agreement shall survive such liquidation.

 

21. The Company, the Sponsor and each Insider hereby
acknowledges and agrees that the Representative on behalf of the Underwriters are third party beneficiaries of this Letter Agreement.

[Signature Page Follows] 

    	 	 	 

    	 	 	 

    

 

	 	Sincerely,
	 	 
	 	BRIGHT VISION SPONSOR LLC
	 	 	 
	 	By:	/s/ Ke Li 
	 	 	Name:	 Ke Li
	 	 	Title:	Managing Member

 

	 	I-BANKERS SECURITIES, INC.
	 	 	 
	 	By:	/s/ Shelley Leonard 
	 	 	Name:	 Shelley Leonard
	 	 	Title:	 President

 

	 	By:	/s/ Humphrey P. Polanen 
	 	 	Name:	 Humphrey P. Polanen

 

	 	By:	/s/ Weixuan Luo 
	 	 	Name:	 Weixuan Luo

 

	 	By:	/s/ Ronald M. Razmi, MD 
	 	 	Name:	 Ronald M. Razmi, MD

 

	 	By:	/s/ Tina Spires 
	 	 	Name:	 Tina Spires

 

	 	By:	/s/ HongLiang Ren 
	 	 	Name:	 HongLiang Ren

 

	 	By:	/s/ Bryant E. Fong 
	 	 	Name:	 Bryant E. Fong

 

	 	By:	/s/ Marc A. Hamer 
	 	 	Name:	 Marc A. Hamer

 

	 	By:	/s/ Wanlei Miao 
	 	 	Name:	 Wanlei Miao

 

 

	Acknowledged and Agreed:	 
	 	 
	DEEP MEDICINE ACQUISITION CORP.	 
	 	 	 
	By:	/s/ Humphrey P. Polanen 	 
	 	Name:	 Humphrey P. Polanen	 
	 	Title: 	Chief Executive Officer	 

 

[Signature Page to Letter Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]